Victoria E. Brown

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 146 citations · Full text

CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination

Victoria E. Brown, Sydney L. Moore, Maxine Chen et al. · NAR Cancer · 2023 · 25 citations · Full text

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

Chiara Conti, John Campbell, Rich Woessner et al. · Cancer Research · 2021 · 24 citations

Metastatic Nsclc, Pathology, Kinase Inhibitors +21

Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i> -Aberrant Ovarian and Endometrial Tumors

Nealia C. House, Victoria E. Brown, Maxine Chen et al. · Cancer Research · 2025 · 14 citations · Full text

Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in <i>CCNE1</i>-amplified ovarian cancer models

Victoria E. Brown, Phil Ramsden, Nealia C. House et al. · Cancer Research · 2022 · 11 citations